

## Special Issue

# Drugs and Drug Delivery for Diabetes Mellitus Treatment, 2nd Edition

### Message from the Guest Editors

Diabetes is an epidemic disease with a prevalence that will double over the next 20 years. Diabetic macular oedema is the main cause of visual impairment in young people under 50. Screening for diabetic retinopathy is essential and is increasingly assisted by artificial intelligence. The classification of diabetic retinopathy is now quite old and must evolve, particularly with the help of OCT. Diagnosis has become multimodal. Numerous treatments exist, from anti-VEGF to steroids, with short- or long-acting molecules. This Special Issue in *Pharmaceutics* to be quite open about the ophthalmological damage of diabetes, from diabetic retinopathy to diabetic macular oedema, more specifically dedicated to its therapeutic management. Indeed, I would like to receive original articles about new molecules with new drug molecular structures, new pathways of action, new mechanisms of action, new combination therapies or even biosimilars. Articles on short, medium or long delivery systems, such as implants, are welcome, especially on steroids, which are classical in DME management.

### Guest Editors

Prof. Dr. Laurent Kodjikian

Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon 1, 69004 Lyon, France

Dr. Thibaud Mathis

Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon 1, 69004 Lyon, France

### Deadline for manuscript submissions

closed (30 October 2024)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/174637](https://mdpi.com/si/174637)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).